SOPHiA GENETICS CSO sells 7,393 shares for taxes

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 7,393 Ordinary Shares in an open-market transaction at a weighted average price of $5.1727 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 7,393 Ordinary Shares in an open-market transaction at a weighted average price of $5.1727 per share. The sale was executed to cover tax withholding obligations from recent restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and does not represent a discretionary trade. Following this transaction, Xu directly holds 614,887 Ordinary Shares, indicating he retains a large continuing stake in the company.

Insider Trade Summary 10b5-1

Net Seller: 7,393 shares

Net Sell 1 txn

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 7,393 shs ($38K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	7,393	$5.1727	$38K

Holdings After Transaction: Ordinary Shares — 614,887 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 7,393 shares Weighted average sale price: $5.1727 per share Post-transaction holdings: 614,887 shares +2 more

5 metrics

Shares sold 7,393 shares Open-market sale on July 6, 2026

Weighted average sale price $5.1727 per share Ordinary Shares sale to cover tax withholding

Post-transaction holdings 614,887 shares Ordinary Shares directly owned after sale

Sale price range $4.97–$5.43 per share Multiple transactions within this price band

Net share change -7,393 shares Net-sell direction from transaction summary

Key Terms

restricted stock units, Rule 10b5-1(c) trading plan, weighted average price, open market

4 terms

restricted stock units financial

"arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SOPHiA GENETICS (SOPH) shares did Zhenyu Xu sell in this Form 4?

Zhenyu Xu sold 7,393 Ordinary Shares of SOPHiA GENETICS SA. These shares were sold in an open-market transaction to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than as a discretionary portfolio decision.

What price did Zhenyu Xu receive per SOPHiA GENETICS (SOPH) share in the reported sale?

The reported price is a weighted average of $5.1727 per share. According to the filing, individual trades occurred at prices ranging from $4.97 to $5.43, and detailed breakdowns are available from the company or SEC staff upon request.

Why did SOPHiA GENETICS (SOPH) executive Zhenyu Xu sell shares according to this Form 4?

The sale was made to satisfy tax withholding obligations from restricted stock units vesting on July 2 and July 3, 2026. The filing explains these were mechanistic tax-related sales, not discretionary trades expressing a view on the company’s valuation.

Was Zhenyu Xu’s SOPHiA GENETICS (SOPH) share sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were executed under a pre-established Rule 10b5-1(c) trading plan. Such plans schedule trades in advance, reducing the significance of trade timing as an indicator of the insider’s short-term outlook.

How many SOPHiA GENETICS (SOPH) shares does Zhenyu Xu hold after this Form 4 transaction?

After the reported sale, Zhenyu Xu directly holds 614,887 Ordinary Shares. This remaining position shows that the tax-related sale represented only a small portion of his overall direct ownership in SOPHiA GENETICS SA.

What role does Zhenyu Xu hold at SOPHiA GENETICS (SOPH) in this insider filing?

Zhenyu Xu is identified as the Chief Scientific Officer of SOPHiA GENETICS SA. His Form 4 filing reports a tax-related sale of company shares following restricted stock unit vesting, while maintaining a substantial continuing equity stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		S		7,393(1)	D	$5.1727(2)	614,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2 and July 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)